Bavar­i­an Nordic aban­dons Covid boost­er af­ter da­ta show it's not as ef­fec­tive against new vari­ants

Bavar­i­an Nordic is aban­don­ing its Covid-19 boost­er vac­cine af­ter Phase III re­sults — even though it did hit the pri­ma­ry end­point of the study — be­cause it’s not as ef­fec­tive against new­er vari­ants of the virus.

The cap­sid virus-like par­ti­cle (cVLP) based boost­er, called AB­N­CoV2, did low­er the lev­els of neu­tral­iz­ing an­ti­bod­ies against the orig­i­nal SARS-CoV-2 vari­ant. But even if the da­ta found that it was non-in­fe­ri­or to the par­tic­i­pants in the study who were vac­ci­nat­ed with Pfiz­er and BioN­Tech’s Comir­naty, it was for a vari­ant that is “no longer the pri­ma­ry con­cern,” Bavar­i­an said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER